Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers

Background. Vitamin D deficiency is frequently observed in end-stage renal disease (ESRD) patients; however, the effects of vitamin D supplementation have rarely been reported. We aimed to assess the effects of daily 25(OH)D3 supplementation on mineral metabolism, bone markers and Kidney Disease Out...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2008-11, Vol.23 (11), p.3670-3676
Main Authors: Jean, Guillaume, Terrat, Jean-Claude, Vanel, Thierry, Hurot, Jean-Marc, Lorriaux, Christie, Mayor, Brice, Chazot, Charles
Format: Article
Language:English
Subjects:
25-hydroxyvitamin D
Administration, Oral
Aged
Aged, 80 and over
Alkaline Phosphatase - metabolism
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Biomarkers - metabolism
Bone and Bones - metabolism
Bone Density Conservation Agents - therapeutic use
bone markers
Calcifediol - administration & dosage
Calcifediol - therapeutic use
Calcium - blood
Dietary Supplements
Dose-Response Relationship, Drug
Emergency and intensive care: renal failure. Dialysis management
Female
General and cellular metabolism. Vitamins
haemodialysis
Humans
Hydroxycholecalciferols - therapeutic use
Intensive care medicine
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Medical sciences
Middle Aged
mineral metabolism
Outcome Assessment (Health Care)
Pharmacology. Drug treatments
Phosphorus - blood
Renal Dialysis
Vitamin D - administration & dosage
Vitamin D - therapeutic use
vitamin D deficiency
Vitamin D Deficiency - drug therapy
Vitamin D Deficiency - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Vitamin D deficiency is frequently observed in end-stage renal disease (ESRD) patients; however, the effects of vitamin D supplementation have rarely been reported. We aimed to assess the effects of daily 25(OH)D3 supplementation on mineral metabolism, bone markers and Kidney Disease Outcomes Quality Initiative (KDOQI) targets in haemodialysis (HD) patients for a period of 6 months. Methods. HD patients were included in this study if their serum 25(OH)D level was
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfn339